Search

Your search keyword '"Schnider, Peter"' showing total 34 results
Start Over Author "Schnider, Peter"
34 results on '"Schnider, Peter"'

2. Analysis of inflammatory markers and tau deposits in an autopsy series of nine patients with anti-IgLON5 disease

Author

Berger-Sieczkowski, Evelyn, Endmayr, Verena, Haider, Carmen, Ricken, Gerda, Jauk, Philipp, Macher, Stefan, Pirker, Walter, Högl, Birgit, Heidbreder, Anna, Schnider, Peter, Bradley-Zechmeister, Eszter, Mariotto, Sara, Koneczny, Inga, Reinecke, Raphael, Kasprian, Gregor, Weber, Corinna, Bergmann, Melanie, Milenkovic, Ivan, Berger, Thomas, Gaig, Carles, Sabater, Lidia, Graus, Francesc, Gelpi, Ellen, and Höftberger, Romana

Published
2023
Full Text
View/download PDF

3. CXCL13 as a biomarker in the diagnostics of European lyme Neuroborreliosis - A prospective multicentre study in Austria.

Author

Waiß, Christoph, Ströbele, Barbara, Graichen, Uwe, Klee, Sascha, Gartlehner, Joshua, Sonntagbauer, Estelle, Hirschbichler, Stephanie, Tinchon, Alexander, Kacar, Emrah, Wuchty, Bianca, Novotna, Bianka, Kühn, Zofia, Sellner, Johann, Struhal, Walter, Bancher, Christian, Schnider, Peter, Asenbaum-Nan, Susanne, and Oberndorfer, Stefan

Abstract

Background: 'Definite Neuroborreliosis (NB)' is diagnosed with the presence of NB-specific symptoms, cerebrospinal fluid (CSF) pleocytosis and an elevated Borrelia Burgdorferi antibody index. However, some diagnostic uncertainties exist. The B-cell chemokine CXCL13 represents an emerging biomarker for the diagnosis and treatment of NB because its intrathecal concentration rises prior to the Borrelia antibody index and drops rapidly after antibiotic therapy. Nevertheless, due to lacking prospective data, a definite CXCL13 cut-off for the diagnosis of NB is still pending. Objective: Definition of a CSF CXCL13 cut-off for the diagnosis of acute and untreated NB in a prospective study setting. Design and methods: This multicentre prospective study involved 6 neurological departments treating patients in the Lower Austria district (1.7 million inhabitants). The controls were patients scheduled for a spinal tap but not clinically diagnosed with NB. Demographic data, clinical characteristics and blood counts, as well as inflammatory CSF values and CSF CXCL13-concentration were analysed. Results: We recruited 440 adult patients, of whom 42 have been diagnosed as having an acute and untreated 'definite NB'. Three hundred ninety-eight patients were assigned to the control group. The median intrathecal CXCL13 concentration was 2384 pg/ml for patients with NB and 0 pg/ml for controls. The difference was highly statistically significant (P ≤.001). A CSF CXCL13 cut-off of 271 pg/ml resulted in a sensitivity of 95.2% and a specificity of 97.2% for the confirmation or exclusion of NB. Conclusion: Based on our results, we propose a CSF CXCL13 cut-off of 271 pg/ml with Euroimmun-Elisa for the diagnosis of acute and untreated NB. Due to its high sensitivity and specificity, CXCL13 is a strong candidate biomarker for routine NB assessment, especially in clinically unclear cases. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Temporal Trends of Functional Outcome in Patients With Acute Ischemic Stroke Treated With Intravenous Thrombolysis

Author

Marko, Martha, primary, Miksova, Dominika, additional, Ebner, Johanna, additional, Lang, Marie, additional, Serles, Wolfgang, additional, Sommer, Peter, additional, Sykora, Marek, additional, Lang, Wilfried, additional, Knoflach, Michael, additional, Kiechl, Stefan, additional, Greisenegger, Stefan, additional, Mutzenbach, Johannes Sebastian, additional, Bubel, Nele, additional, Zellner, Thomas, additional, Krstic, Miroslav, additional, Grandits, Waltraud, additional, Katzenschlager, Regina, additional, Vosko, Milan R., additional, von Örzten, Tim, additional, Struhal, Walter, additional, Brunner, Cornelia, additional, Yilmaz-Kaymaz, Nilguen, additional, Hosseiny, Omid, additional, Krisper, Eva, additional, Säckl, Felix, additional, Baumgartner, Christoph, additional, Rumpl, Elke, additional, Pirker-Kees, Agnes, additional, Berger, Otto, additional, Beirer, Sebastian, additional, Komenda-Lett, Martin, additional, Weber, Jörg R., additional, Höfner, Elmar, additional, Seiler, Stephan, additional, Berek, Klaus, additional, Mayr, Markus, additional, Haaser, Stefan, additional, Asenbaum-Nan, Susanne, additional, Heumesser, Rebecca, additional, Rumpl, Barbara Almut, additional, Rus, Marc, additional, Muellauer, Barbara, additional, Höger, Franz, additional, Lampl, Christian, additional, Bocksrucker, Christof, additional, Lackner, Peter, additional, Schlager, Markus, additional, Mayer, Florian, additional, Fertl, Elisabeth, additional, Steiner, Sandrina, additional, Koller, Herbert, additional, Doppler, Wolfgang, additional, Ferrari, Julia, additional, Krebs, Stefan, additional, Mitrovic, Nenad, additional, Salletmayr, Thomas, additional, Grunenberg, Monika, additional, Bancher, Christian, additional, Pinter, Hajnalka, additional, Karpat, Frantisek, additional, Sellner, Johann, additional, Wolf, Thomas, additional, Schnider, Peter, additional, Wallner-Blazek, Mirja, additional, Enzinger, Christian, additional, Gattringer, Thomas, additional, Poltrum, Birgit, additional, Böhme, Christian, additional, Mayer, Lukas, additional, Hofeneder, Dominik, additional, Daniel, Gerhard, additional, Kaniak, Kitty, additional, Grossmann, Josef, additional, Morgenstern, Gabi, additional, Wendlinger, Nadja, additional, Staykov, Dimitre, additional, Halilovic, Almin, additional, Frattner, Michael, additional, Waiß, Christoph, additional, Tinchon, Alexander, additional, Fischer, Anna, additional, Kapeller, Peter, additional, Luschin, Gerda, additional, Gasser, Sibylle, additional, Heine, Martin, additional, Wurzinger, Harald, additional, Wührer, Susanne, additional, Werner, Philipp, additional, Mayr, Andrea, additional, Matosevic, Benjamin, additional, Gollmer, A., additional, and Kern, R., additional

Published
2022
Full Text
View/download PDF

7. Prevention of poststroke cognitive decline: ASPIS – a multicenter, randomized, observer-blind, parallel group clinical trial to evaluate multiple lifestyle interventions – study design and baseline characteristics

Author

Brainin, Michael, Matz, Karl, Nemec, Matthias, Teuschl, Yvonne, Dachenhausen, Alexandra, Asenbaum-Nan, Susanne, Bancher, Christian, Kepplinger, Berthold, Oberndorfer, Stefan, Pinter, Michaela, Schnider, Peter, and Tuomilehto, Jaakko

Published
2015
Full Text
View/download PDF

12. Uses of botulinum toxin

Author

Schnider, Peter, Binder, Michael, Kittler, Harald, Steinhoff, Nikolaus, and Auff, Eduard

Published
1997

14. Dynamic changes of plasma lipids and lipoproteins in patients after transient ischemic attack or minor stroke

Author

Aull, Susanne, Lalouschek, Wolfgang, Schnider, Peter, Sinzinger, Helmut, Uhl, Frank, and Zeiler, Karl

Subjects
Heart attack -- Physiological aspects, Stroke (Disease) -- Physiological aspects, Blood lipids -- Physiological aspects, Blood lipoproteins -- Physiological aspects, Health, Health care industry
Abstract

PURPOSE: Only few data are available concerning variations of lipids and lipoproteins in the acute stage after ischemic cerebrovascular events. It was the aim of this study to investigate whether the lipid and lipoprotein levels obtained in the first few days after a transient ischemic attack (TIA) or a minor stroke (MS) actually reflect `correct' values or `changed' (ie, false low) values, as in patients after acute myocardial infarction. PATIENTS AND METHODS: Total cholesterol (TC), HDL-cholesterol (HDL-C), LDL-cholesterol (LDL-C), and triglyceride (TG) levels of 37 unselected patients with TIA or MS were determined within 12-48 hours (Group A) or within 49-168 hours (Group B) after the acute event. After a mean observation period of 15.3 months, all patients were re-examined; the results were compared with those of the baseline evaluation. RESULTS: At the time of the baseline evaluation, TC and LDL-C levels of Group B patients were significantly lower than Group A levels. At the end of the observation period, however, Group A and Group B patients did not differ with regard to all four parameters. In comparison with the baseline examination, the values of Group A patients had not changed. In Group B patients, however, TC, HDL-C, LDL-C, and TG levels had significantly increased. CONCLUSION: Our results strongly suggest that lipid and lipoprotein levels of patients with TIA or MS should be assessed within a maximum of 48 hours after the acute event. If the examination cannot be performed within that period, the determination of reliable values is possible only after several weeks or months. Am J Med. 1996;101:291-298.

Published
1996

19. European Consensus Table On the Use of Botulinum Toxin Type a in Adult Spasticity

Author

UCL - MD/IEPR - Institut d'éducation physique et de réadaptation, UCL - (SLuc) Service de médecine physique et de réadaptation motrice, UCL - (MGD) Service de médecine physique et revalidation, UCL - SSS/IONS - Institute of NeuroScience, Wissel, Jörg, Ward, Anthony B., Erztgaard, Per, Bensmail, Djamel, Hecht, Martin J., Lejeune, Thierry, Schnider, Peter, Deltombe, Thierry, UCL - MD/IEPR - Institut d'éducation physique et de réadaptation, UCL - (SLuc) Service de médecine physique et de réadaptation motrice, UCL - (MGD) Service de médecine physique et revalidation, UCL - SSS/IONS - Institute of NeuroScience, Wissel, Jörg, Ward, Anthony B., Erztgaard, Per, Bensmail, Djamel, Hecht, Martin J., Lejeune, Thierry, Schnider, Peter, and Deltombe, Thierry

Abstract

A group of clinicians from across Europe experienced in the use of botulinum toxin type a for the treatment of spasticity following acquired brain injury gathered to develop a consensus statement on best practice in managing adults with spasticity. this consensus table summarizes the current published data, which was collated following extensive literature searches, their assessment for level of evidence and discussion among the whole group. published information is supplemented by expert opinion based on clinical experience from 16 European countries, involving 28 clinicians, who treat an average of approximately 200 patients annually, representing many thousand spasticity treatments with botulinum toxin per year.

Published
2009

20. EUROPEAN CONSENSUS TABLE ON THE USE OF BOTULINUM TOXIN TYPE A IN ADULT SPASTICITY

Author

Wissel, Joerg, Ward, Anthony B, Erztgaard, Per, Bensmail, Djamel, Hecht, Martin J, Lejeune, Thierry M, Schnider, Peter, Wissel, Joerg, Ward, Anthony B, Erztgaard, Per, Bensmail, Djamel, Hecht, Martin J, Lejeune, Thierry M, and Schnider, Peter

Abstract

A group of clinicians from across Europe experienced in the use of botulinum toxin type a for the treatment of spasticity following acquired brain injury gathered to develop a consensus statement on best practice in managing adults with spasticity. this consensus table summarizes the current published data, which was collated following extensive literature searches, their assessment for level of evidence and discussion among the whole group. published information is supplemented by expert opinion based on clinical experience from 16 European countries, involving 28 clinicians, who treat an average of approximately 200 patients annually, representing many thousand spasticity treatments with botulinum toxin per year.

Published
2009
Full Text
View/download PDF

21. Prevention of Poststroke Cognitive Decline: ASPIS – a Multicenter, Randomized, Observer-Blind, Parallel Group Clinical Trial to Evaluate Multiple Lifestyle Interventions – Study Design and Baseline Characteristics

Author

Brainin, Michael, primary, Matz, Karl, additional, Nemec, Matthias, additional, Teuschl, Yvonne, additional, Dachenhausen, Alexandra, additional, Asenbaum-Nan, Susanne, additional, Bancher, Christian, additional, Kepplinger, Berthold, additional, Oberndorfer, Stefan, additional, Pinter, Michaela, additional, Schnider, Peter, additional, and Tuomilehto, Jaakko, additional

Published
2013
Full Text
View/download PDF

34. European consensus table on the use of botulinum toxin type A in adult spasticity.

Author

Wissel J, Ward AB, Erztgaard P, Bensmail D, Hecht MJ, Lejeune TM, Schnider P, Altavista MC, Cavazza S, Deltombe T, Duarte E, Geurts AC, Gracies JM, Haboubi NH, Juan FJ, Kasch H, Kätterer C, Kirazli Y, Manganotti P, Parman Y, Paternostro-Sluga T, Petropoulou K, Prempeh R, Rousseaux M, Slawek J, and Tieranta N

Subjects
Adult, Brain Injury, Chronic complications, Consensus, Evidence-Based Medicine, Follow-Up Studies, Humans, Hypoxia, Brain complications, Injections, Intramuscular, Motor Activity drug effects, Motor Neuron Disease etiology, Muscle Spasticity etiology, Stroke complications, Botulinum Toxins, Type A administration & dosage, Motor Neuron Disease drug therapy, Muscle Spasticity drug therapy, Neuromuscular Agents administration & dosage
Abstract

A group of clinicians from across Europe experienced in the use of botulinum toxin type A for the treatment of spasticity following acquired brain injury gathered to develop a consensus statement on best practice in managing adults with spasticity. This consensus table summarizes the current published data, which was collated following extensive literature searches, their assessment for level of evidence and discussion among the whole group. Published information is supplemented by expert opinion based on clinical experience from 16 European countries, involving 28 clinicians, who treat an average of approximately 200 patients annually, representing many thousand spasticity treatments with botulinum toxin per year.

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results